Global Burden of Disease Study

(Pr)VYEPTI® (eptinezumab for injection) is now available

Retrieved on: 
星期二, 十一月 1, 2022
Migraine, Lundbeck, Disease, Neurological disorder, Headache, Adult, Injury, YLD, Common, General manager, Statistics Canada, Physician, Nausea, III, Vomiting, Lancet, Safety, Sound, Disability, Eptinezumab, CGRP, Woman, Light, Patient, Prevalence, Global Burden of Disease Study, MMD, IV, Incidence, Calcitonin, Ageing, Health insurance, Pharmaceutical industry, Medical device, Medicinal plants, Aroma compound, Real estate

VYEPTI is indicated for the prevention of migraine in adults who have at least four migraine days per month.

Key Points: 
  • VYEPTI is indicated for the prevention of migraine in adults who have at least four migraine days per month.
  • With VYEPTI, that's especially important because there hasn't been an IV treatment in this therapeutic area before."
  • Lundbeck Canada believes that patient support is a key element to the success of any therapy.
  • "As a new treatment option available to those living with migraine, VYEPTI gives patients another avenue to try, in the pursuit of brain health," said Wendy Gerhart, Executive Director at Migraine Canada.

Study Suggests That Meat Consumption May Reduce Lifespan, Says Dr. Michael Greger of NutritionFacts.org

Retrieved on: 
星期三, 九月 14, 2022
Global Burden of Disease Study, Vegetable, Woman, Union, Union of Concerned Scientists, Eating, Meat, Life, Diabetes, Degenerative disease, Cancer, Concerned Scientists, Death, Research, Man, The New York Times, Exercise, Fast food, Diet

Eating meat-heavy diets results in millions of healthy years of life lost every year around the worldand it doesn't take much.

Key Points: 
  • Eating meat-heavy diets results in millions of healthy years of life lost every year around the worldand it doesn't take much.
  • The Union of Concerned Scientists estimated that thousands of annual cancer deaths could be averted if Americans cut down meat intake to just one ounce a week.
  • Physician and author of The New York Times bestsellers How Not to Die and How Not to Diet, Michael Greger, M.D.
  • FACLM, weighs in: "It is as if each burger a person consumes is taking 30 minutes off their life.

Heru Expands Wearable Platform with Launch of Dark Adaptation, Establishing Market-Leading AMD Portfolio

Retrieved on: 
星期三, 九月 14, 2022
Research, Technology, Medical Devices, Software, Biotechnology, Hardware, General Health, Health, Optical, Science, Dark, Adaptation, Age-Related Eye Disease Study, AR, MD, Prevalence, Visual impairment, Global Burden of Disease Study, Vision, OCT, Compliance, Health, Drusen, Adaptation (eye), Industry, Field line, Severe cognitive impairment, Patient, Consultant, Physician, CEO, Doctor of Philosophy, PMID, Insurance, Research, AMD, Multimedia, University, OD, Disease, Medical imaging, Central Europe

View the full release here: https://www.businesswire.com/news/home/20220914005233/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220914005233/en/
    Heru adds new testing modality, Dark Adaptation, to its one-of-a-kind, wearable vision screening platform.
  • We are incredibly pleased to announce the release of dark adaptation further advancing our platform and delivering on our commitment to establish a comprehensive wearable AMD portfolio, said Mohamed Abou Shousha, MD, PhD, CEO, and founder of Heru.
  • Dark adaptation testing with the Heru platform is something we have been excited about adopting in our practice.
  • With Heru, we are better equipped to detect dark adaptation impairment which studies have shown to be an early indicator of AMD.

Global Molecular Diagnostics Market Report 2022-2028: Increase in Demand for Point-of-Care and Developments by Market Players & Prevalence of Associated Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
星期二, 八月 9, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Death, Animal and Plant Health Inspection Service, Global Burden of Disease Study, World Health Organization, Genetic testing, Mortality, Population, Technology, POC, European Medical Writers Association, American Cancer Society, Cancer, Infection, Hospital, Prevalence, Research, Food and Drug Administration, Patient, DNA, COVID-19, Lists of diseases, CVD, Polymerase chain reaction, Institute for Health Metrics and Evaluation, CAGR, WHO, World, Food safety, Software, European Medical Association, Food, Food Safety and Inspection Service, Pharmaceutical industry, Vaccine, Medical device

The "Molecular Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The market growth is mainly attributed to an increase in demand for point-of-care devices, developments by market players, and a rise in the prevalence of associated diseases.
  • However, the increasing prevalence of associated diseases is expected to limit market growth.
  • Molecular diagnostics has wide applications in various indications such as oncology, infectious diseases, genetic testing, cardiac diseases, and immune system disorders.

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

Retrieved on: 
星期二, 七月 5, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Efficiency, Patient, Severity, Research, Senior, Â, Hearing, AAV, TSE, Hearing loss, Global Burden of Disease Study, Sensorineural hearing loss, CSO, Differentiable function, Lancet, Factor X, Regenerative medicine, Disease, Ear, Disability, Prevalence, Limited, Quality of life, VP, Gene, Therapy, Pharmaceutical industry, Medical device, Astellas Pharma

An estimated 1.57 billion people globally suffer from hearing loss1, and US data suggests that over 10% have severe to profound sensorineural hearing loss in at least one ear2.

Key Points: 
  • An estimated 1.57 billion people globally suffer from hearing loss1, and US data suggests that over 10% have severe to profound sensorineural hearing loss in at least one ear2.
  • This degree of hearing loss significantly reduces quality of life and, with no drug treatments currently available, represents a large unmet need.
  • Combined with Astellas capabilities for gene therapy and research of sensorineural, this provides a clear path for the development of a novel in vivo reprogramming therapy for sensorineural hearing loss.
  • Through this collaboration, we will seek to address a significant unmet need in sensorineural hearing loss.

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

Retrieved on: 
星期二, 七月 5, 2022
Efficiency, University, Nature Genetics, Patient, Modality, Severity, Research, Senior, Therapy, Ophthalmology, Hearing, AAV, TSE, Advertising, Company, Hearing loss, Industry, Sensorineural hearing loss, Global Burden of Disease Study, Cell Systems, CSO, Differentiable function, Lancet, Factor X, Regenerative medicine, Disease, Degenerative disease, Ear, Disability, Prevalence, RNA, Quality of life, OBE, VP, Technology, Gene, Glossary, Maintenance, Biology, Knowledge, Hope, Multimedia, Doctor of Philosophy, Pharmaceutical industry, Vaccine, Medical device, Astellas Pharma

An estimated 1.57 billion people globally suffer from hearing loss1, and US data suggests that over 10% have severe to profound sensorineural hearing loss in at least one ear2.

Key Points: 
  • An estimated 1.57 billion people globally suffer from hearing loss1, and US data suggests that over 10% have severe to profound sensorineural hearing loss in at least one ear2.
  • This degree of hearing loss significantly reduces quality of life and, with no drug treatments currently available, represents a large unmet need.
  • Combined with Astellas' capabilities for gene therapy and research of sensorineural, this providesa clear path for the development of a novel in vivo reprogramming therapy forsensorineural hearing loss."
  • Through this collaboration,we will seek to address a significant unmet need in sensorineural hearing loss.

Research launched at Global Forum on Nicotine shows WHO's tobacco control measures are failing - and that harm reduction works

Retrieved on: 
星期五, 六月 17, 2022
Smoker, Tobacco, Mortality, Smoking, Framework convention, Science, Global Burden of Disease Study, WHO, Association, FCTC, Man, Research, TCS, Sale, WHO Framework Convention on Tobacco Control, Disease burden, Male, Woman, Nicotine, EU

WARSAW, Poland, June 17, 2022 /PRNewswire/ -- A new study launched at the ninth annual Global Forum on Nicotine (#GFN22) in Warsaw shows implementation of the WHO's tobacco control measures known as MPOWER has no clear association with low-levels of tobacco-related mortality in Europe.

Key Points: 
  • WARSAW, Poland, June 17, 2022 /PRNewswire/ -- A new study launched at the ninth annual Global Forum on Nicotine (#GFN22) in Warsaw shows implementation of the WHO's tobacco control measures known as MPOWER has no clear association with low-levels of tobacco-related mortality in Europe.
  • Instead, the independent research , conducted by distinguished tobacco dependence researcher Dr Lars M. Ramstrm , shows that switching from smoking to Swedish-style snus, a safer nicotine product, is a more effective strategy to reduce the harms caused by tobacco.
  • Presented to hundreds of delegates, as well as over 50 international experts on tobacco and nicotine science who are speaking at #GFN22, the new findings provide further evidence that the WHO must embrace tobacco harm reduction as part of its global tobacco control response by supporting the use of safer nicotine products to quit smoking.
  • Comprising six measures, it aims to reduce the demand for tobacco.

Research launched at Global Forum on Nicotine shows WHO's tobacco control measures are failing - and that harm reduction works

Retrieved on: 
星期五, 六月 17, 2022
Smoker, Tobacco, Mortality, Smoking, Framework convention, Science, Global Burden of Disease Study, WHO, Association, FCTC, Man, Research, TCS, Sale, WHO Framework Convention on Tobacco Control, Disease burden, Male, Woman, Nicotine, EU

WARSAW, Poland, June 17, 2022 /PRNewswire/ -- A new study launched at the ninth annual Global Forum on Nicotine (#GFN22) in Warsaw shows implementation of the WHO's tobacco control measures known as MPOWER has no clear association with low-levels of tobacco-related mortality in Europe.

Key Points: 
  • WARSAW, Poland, June 17, 2022 /PRNewswire/ -- A new study launched at the ninth annual Global Forum on Nicotine (#GFN22) in Warsaw shows implementation of the WHO's tobacco control measures known as MPOWER has no clear association with low-levels of tobacco-related mortality in Europe.
  • Instead, the independent research , conducted by distinguished tobacco dependence researcher Dr Lars M. Ramstrm , shows that switching from smoking to Swedish-style snus, a safer nicotine product, is a more effective strategy to reduce the harms caused by tobacco.
  • Presented to hundreds of delegates, as well as over 50 international experts on tobacco and nicotine science who are speaking at #GFN22, the new findings provide further evidence that the WHO must embrace tobacco harm reduction as part of its global tobacco control response by supporting the use of safer nicotine products to quit smoking.
  • Comprising six measures, it aims to reduce the demand for tobacco.

Worldwide Orthodontic Supplies Industry to 2028 - Growing Prevalence of Dental Problems is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
星期五, 六月 10, 2022
Dental, Health, Global Burden of Disease Study, Dentistry, Overbite, Korea Disease Control and Prevention Agency, Adult, Centers for Disease Control and Prevention, Gingivitis, Disease, Awareness, Government, CDC, Degenerative disease, Center, Growth, COVID-19, Radioactive decay, Prevalence, Population, Orthodontics, Periodontal disease, CAGR, Consciousness

The orthodontic supplies market is projected to reach US$ 11,038.07 million by 2028 from US$ 5,448.86 million in 2021.

Key Points: 
  • The orthodontic supplies market is projected to reach US$ 11,038.07 million by 2028 from US$ 5,448.86 million in 2021.
  • The growth is attributed to various factors such as high prevalence rate of dental problems and irregularities along with the surge in cosmetic dental procedures owing to increasing consciousness about aesthetics.
  • Poor oral hygiene can led to various gum diseases, dental problems, crocked teeth malocclusions, gum disease, periodontal diseases, cavities and others.
  • Thus, Increasing prevalence of dental problems are expected to create demand for orthodontic supplies market driving the market growth.

Lundbeck to Present Data on VYEPTI® (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention

Retrieved on: 
星期四, 六月 9, 2022
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diamond, Woman, Eptinezumab, Neurological disorder, Caregiver, Headache, AHS, Research, Marketing, Lists of diseases, Nausea, Amitriptyline, Disease, Headache (journal), MHD, Steiner, Global Burden of Disease Study, Migraine, Failure, WPAI, CGRP, Disability, Patient, YLD, VAS, Calcitonin gene-related peptide, Topiramate, MSQ, Poster, LUN, Vomiting, Birth control, Pharmaceutical industry, Medical imaging, Aroma compound, Lundbeck, Virtual Private LAN Service

Lundbeck today announced data on VYEPTI (eptinezumab-jjmr) will be presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS) taking place from June 9-12, 2022.

Key Points: 
  • Lundbeck today announced data on VYEPTI (eptinezumab-jjmr) will be presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS) taking place from June 9-12, 2022.
  • A total of nine poster presentations will be shared to highlight clinical data and real-world analyses of eptinezumab as a preventive migraine treatment in adults.
  • These data continue to show the clinical benefit of VYEPTI as a preventive treatment option for people with migraine, said Marija Geertsen, M.D., Vice President, U.S. Medical Affairs, Lundbeck.
  • The safety of VYEPTI was evaluated in 2,076 patients with migraine who received at least one dose of VYEPTI.